Cellectis Unveils 2026 Strategy and Key Milestones for Lasme-cel and Eti-cel Trials.
ByAinvest
Thursday, Jan 8, 2026 4:32 pm ET1min read
CLLS--
Cellectis has outlined its 2026 strategy, focusing on the pivotal Phase 2 BALLI-01 trial for lasme-cel in r/r B-ALL, with interim data expected in Q4. The company also expects to present the full Phase 1 data of the NATHALI-01 trial for eti-cel in NHL in Q4. Additionally, Cellectis is leveraging the momentum of its strategic partnership with AstraZeneca.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet